Skip to main content

Afinitor Disperz and Alcohol/Food Interactions

There are 2 alcohol/food/lifestyle interactions with Afinitor Disperz (everolimus).

Moderate

Everolimus Food

Moderate Food Interaction

GENERALLY AVOID: Grapefruit juice may significantly increase the plasma concentrations of orally administered everolimus. The mechanism is inhibition of CYP450 3A4 and P-glycoprotein activity in the gut wall by certain compounds present in grapefruit.

MANAGEMENT: Patients treated with everolimus should avoid consumption of grapefruit and grapefruit juice.

References (1)
  1. (2009) "Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals

Switch to consumer interaction data

Moderate

Everolimus High Cholesterol (Hyperlipoproteinemia, Hypertriglyceridemia, Sitosterolemia)

Moderate Potential Hazard, Moderate plausibility

mTOR inhibitors - cholesterol

Elevations in cholesterol and triglyceride levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin). Monitoring of fasting lipid profile is recommended prior to the start of therapy and periodically thereafter. Clinicians should achieve control of lipid levels before initiating therapy with these agents.

References (2)
  1. (2007) "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories
  2. (2009) "Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals

Switch to consumer interaction data

Afinitor Disperz drug interactions

There are 547 drug interactions with Afinitor Disperz (everolimus).

Afinitor Disperz disease interactions

There are 8 disease interactions with Afinitor Disperz (everolimus) which include:

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer